MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics (NASDAQ: MLTX) was upgraded by analysts at Wedbush to a "strong-buy" rating.